These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38532079)

  • 1. Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
    Lechowicz MJ; Smith C; Ristuccia R; Dwyer K
    Int J Hematol; 2024 Jun; 119(6):736-744. PubMed ID: 38532079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
    Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
    J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
    Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
    Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
    Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
    J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
    Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the risk for graft
    Kamada Y; Arima N; Hayashida M; Nakamura D; Yoshimitsu M; Ishitsuka K
    Leuk Lymphoma; 2022 Jul; 63(7):1701-1707. PubMed ID: 35225126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Haploidentical transplantation using post-transplant high-dose cyclophosphamide for adult T-cell lymphoma after mogamulizumab treatment].
    Kusakabe M; Kurita N; Nishikii H; Sato R; Yoshida C; Yokoyama Y; Sakata-Yanagimoto M; Obara N; Hasegawa Y; Chiba S
    Rinsho Ketsueki; 2017; 58(5):449-454. PubMed ID: 28592758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with mogamulizumab followed by allogeneic hematopoietic stem-cell transplantation in adult T-cell leukemia/lymphoma: a report of two cases.
    Tsubokura Y; Satake A; Hotta M; Yoshimura H; Fujita S; Azuma Y; Nakanishi T; Nakaya A; Ito T; Ishii K; Nomura S
    Int J Hematol; 2016 Dec; 104(6):744-748. PubMed ID: 27573760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
    Ishitsuka K; Yasukawa T; Tsuji Y
    Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adult T cell leukemia-lymphoma with allo-HSCT after treatment for pulmonary involvement with Mogamulizumab].
    Kawashima I; Sueki Y; Yamamoto T; Nozaki Y; Nakajima K; Mitsumori T; Kirito K
    Rinsho Ketsueki; 2015 Feb; 56(2):210-5. PubMed ID: 25765802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma].
    Fuji S
    Rinsho Ketsueki; 2018; 59(4):426-431. PubMed ID: 29743403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation.
    Trotta GE; Ciangola G; Cerroni I; Mezzanotte V; Nunzi A; Anemona L; Savino L; De Angelis G; Mariotti B; Bonanni F; Meddi E; Zizzari A; Rapisarda VM; Mangione I; Bruno A; Cantonetti M; Venditti A; Cerretti R
    Curr Res Transl Med; 2024 Sep; 72(3):103452. PubMed ID: 38718540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of pretransplant anti-CCR4 antibody administration on clinical outcomes in allogeneic hematopoietic stem cell transplantation].
    Fuji S
    Rinsho Ketsueki; 2019; 60(8):968-972. PubMed ID: 31484897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.
    Weiner DM; Lewis DJ; Spaccarelli NG; Clark RA; Nasta SD; Loren AW; Rook AH; Kim EJ
    Dermatol Ther; 2022 Jul; 35(7):e15538. PubMed ID: 35477952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ureshino H; Kusaba K; Kidoguchi K; Sano H; Nishioka A; Itamura H; Yoshimura M; Yokoo M; Shindo T; Kubota Y; Ando T; Kojima K; Sueoka E; Kimura S
    Ann Hematol; 2019 Feb; 98(2):465-471. PubMed ID: 30264165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide treatment for recurrent adult T-cell leukemia/lymphoma after allogeneic hematopoietic cell transplantation.
    Tanaka T; Inamoto Y; Ito A; Watanabe M; Takeda W; Aoki J; Kim SW; Fukuda T
    Hematol Oncol; 2023 Aug; 41(3):389-395. PubMed ID: 36513602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
    Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
    Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation.
    Inoue Y; Endo S; Matsuno N; Kikukawa Y; Shichijo T; Koga K; Takaki A; Iwanaga K; Nishimura N; Fuji S; Fukuda T; Nosaka K; Matsuoka M
    Bone Marrow Transplant; 2019 Feb; 54(2):338-342. PubMed ID: 30116017
    [No Abstract]   [Full Text] [Related]  

  • 20. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.